CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy
By Ludwig Burger -German biotech CureVac NV said on Wednesday its COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds…










